Article
Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies.
Signal transduction and targeted therapy - 25 Jul 2025
Yuan Ying, Deng Yanhong, Jin Yongdong, Guo Zengqing, Pan Yueyin, Wang Cunji, Wang Zhiwu, Hu Yi, Hua Dong, Meng Xiangjiao, Zhang Zhiye, Zhao Mingfang, Dong Xiaorong, Huang Dingzhi, Li Xiaoyan, Liu Lian, Sun Meili, Wang Huijuan, Wang Xiuwen, Yang Nong, Zhang Mingjun, Hu Sheng, Wu Dongde, Huang Jingjing, Zhang Sujie, Huang Mengna, Ding Kefeng
Abstract excerpt
IBI351 (also known as fulzerasib or GFH925), an irreversible covalent inhibitor of KRASG12C, has demonstrated promising anti-tumour activity in patients with solid tumours. In this study, data were pooled from the phase I part of two clinical studies (NCT05005234 and NCT05497336), aiming to evaluate the efficacy and safety of IBI351 monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated...
Topics
Join the communities discussing this publication.